RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 158 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,562 | -0.6% | 335,024 | -2.9% | 0.00% | 0.0% |
| Q2 2023 | $2,578 | +11.9% | 345,123 | -0.1% | 0.00% | 0.0% |
| Q1 2023 | $2,304 | +82.4% | 345,540 | +110.8% | 0.00% | +50.0% |
| Q4 2022 | $1,263 | -100.0% | 163,909 | -46.1% | 0.00% | -60.0% |
| Q3 2022 | $3,236,000 | +37.3% | 304,212 | +5.0% | 0.01% | +66.7% |
| Q2 2022 | $2,357,000 | +74.3% | 289,609 | +53.3% | 0.00% | +50.0% |
| Q1 2022 | $1,352,000 | -45.0% | 188,924 | +31.8% | 0.00% | -33.3% |
| Q4 2021 | $2,456,000 | – | 143,384 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Obvious Management Services, L.L.C. | 3,985,087 | $42,401,000 | 100.00% |
| Two Sigma Ventures, LP | 903,400 | $9,612,000 | 100.00% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $42,040,000 | 54.37% |
| Data Collective IV GP, LLC | 5,941,120 | $63,214,000 | 49.97% |
| MIC Capital Management UK LLP | 8,451,758 | $89,927,000 | 16.21% |
| MV Management XI, L.L.C. | 1,971,908 | $20,981,000 | 15.20% |
| ArchPoint Investors | 1,116,126 | $11,876,000 | 4.85% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $16,058,000 | 2.00% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,251,971 | $23,961,000 | 1.00% |
| Duquesne Family Office | 1,385,950 | $14,747,000 | 0.84% |